Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bolt Biotherapeutics (BOLT) Revenue (2020 - 2025)

Bolt Biotherapeutics' Revenue history spans 6 years, with the latest figure at $2.2 million for Q3 2025.

  • For Q3 2025, Revenue rose 90.1% year-over-year to $2.2 million; the TTM value through Sep 2025 reached $5.2 million, down 46.88%, while the annual FY2024 figure was $7.7 million, 2.36% down from the prior year.
  • Revenue for Q3 2025 was $2.2 million at Bolt Biotherapeutics, up from $1.8 million in the prior quarter.
  • Across five years, Revenue topped out at $5.3 million in Q1 2024 and bottomed at $508000.0 in Q4 2021.
  • The 5-year median for Revenue is $1.4 million (2022), against an average of $1.7 million.
  • The largest annual shift saw Revenue skyrocketed 188.83% in 2024 before it crashed 76.83% in 2025.
  • A 5-year view of Revenue shows it stood at $508000.0 in 2021, then skyrocketed by 177.76% to $1.4 million in 2022, then surged by 48.05% to $2.1 million in 2023, then tumbled by 45.38% to $1.1 million in 2024, then surged by 90.1% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Revenue are $2.2 million (Q3 2025), $1.8 million (Q2 2025), and $1.2 million (Q1 2025).